These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29572459)

  • 1. Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824).
    Baptista R; Fazakerley DM; Beckmann M; Baillie L; Mur LAJ
    Sci Rep; 2018 Mar; 8(1):5084. PubMed ID: 29572459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assessment of changes to the nontuberculous mycobacterial metabolome in response to anti-TB drugs.
    Drapal M; Wheeler PR; Fraser PD
    FEMS Microbiol Lett; 2018 Aug; 365(15):. PubMed ID: 29945244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the in vivo mechanism of action for drug leads using NMR metabolomics.
    Halouska S; Fenton RJ; Barletta RG; Powers R
    ACS Chem Biol; 2012 Jan; 7(1):166-71. PubMed ID: 22007661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.
    Dogra M; Palmer BD; Bashiri G; Tingle MD; Shinde SS; Anderson RF; O'Toole R; Baker EN; Denny WA; Helsby NA
    Br J Pharmacol; 2011 Jan; 162(1):226-36. PubMed ID: 20955364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and structural investigations on phosphoribosylpyrophosphate synthetase from Mycobacterium smegmatis.
    Donini S; Garavaglia S; Ferraris DM; Miggiano R; Mori S; Shibayama K; Rizzi M
    PLoS One; 2017; 12(4):e0175815. PubMed ID: 28419153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis.
    Yagi A; Uchida R; Hamamoto H; Sekimizu K; Kimura KI; Tomoda H
    J Antibiot (Tokyo); 2017 May; 70(5):685-690. PubMed ID: 28446822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretomanid for the treatment of pulmonary tuberculosis.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Oct; 56(10):655-668. PubMed ID: 33185630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic profiling of dormant Mycolicibacterium smegmatis cells' reactivation reveals a gradual assembly of metabolic processes.
    Nikitushkin VD; Trenkamp S; Demina GR; Shleeva MO; Kaprelyants AS
    Metabolomics; 2020 Feb; 16(2):24. PubMed ID: 32025943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic Analysis of Drug-Resistant Mycobacteria: Co-Evolution of Copper and INH Resistance.
    Chen Y; Yang F; Sun Z; Wang Q; Mi K; Deng H
    PLoS One; 2015; 10(6):e0127788. PubMed ID: 26035302
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Zheng H; Wang Y; He W; Li F; Xia H; Zhao B; Wang S; Shen C; Zhao Y
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0181021. PubMed ID: 34723628
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria.
    Kaur D; Khuller GK
    Int J Antimicrob Agents; 2001 Jan; 17(1):51-5. PubMed ID: 11137649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying and Tackling Emergent Vulnerability in Drug-Resistant Mycobacteria.
    Padiadpu J; Baloni P; Anand K; Munshi M; Thakur C; Mohan A; Singh A; Chandra N
    ACS Infect Dis; 2016 Sep; 2(9):592-607. PubMed ID: 27759382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of four analytical methods to explore skeletal muscle metabolomics: Better coverage of metabolic pathways or a marketing argument?
    Bruno C; Patin F; Bocca C; Nadal-Desbarats L; Bonnier F; Reynier P; Emond P; Vourc'h P; Joseph-Delafont K; Corcia P; Andres CR; Blasco H
    J Pharm Biomed Anal; 2018 Jan; 148():273-279. PubMed ID: 29059617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.
    Piddock LJ; Williams KJ; Ricci V
    J Antimicrob Chemother; 2000 Feb; 45(2):159-65. PubMed ID: 10660497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Establishment and drug susceptibility test of isoniazid resistant Mycobacterium smegmatis].
    Jia PP; Zhao LL; Li XY; Zhang Q; Liu ZL; Wang X; Yu LY; Zhao LX; Cen S
    Yao Xue Xue Bao; 2011 Apr; 46(4):377-82. PubMed ID: 21751489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteomic response of Mycobacterium smegmatis to anti-tuberculosis drugs suggests targeted pathways.
    Wang R; Marcotte EM
    J Proteome Res; 2008 Mar; 7(3):855-65. PubMed ID: 18275136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatis.
    Lu P; Villellas C; Koul A; Andries K; Lill H; Bald D
    J Antibiot (Tokyo); 2014 Dec; 67(12):835-7. PubMed ID: 24916895
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of simultaneous targeted metabolite quantification and untargeted metabolomics strategy using dual-column liquid chromatography coupled with tandem mass spectrometry.
    Gao Y; Chen Y; Yue X; He J; Zhang R; Xu J; Zhou Z; Wang Z; Zhang R; Abliz Z
    Anal Chim Acta; 2018 Dec; 1037():369-379. PubMed ID: 30292313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid.
    López-Gavín A; Tudó G; Vergara A; Hurtado JC; Gonzalez-Martín J
    Int J Antimicrob Agents; 2015 Nov; 46(5):582-5. PubMed ID: 26421981
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.